Year archive

Abbisko Cayman Limited — 2024 filings

All 128 regulatory filings released by Abbisko Cayman Limited (2256) in 2024, sourced directly from the official regulator.

128 Filings

2024 Period

2024 filings (128)

Filing	Released	Lang
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2024-12-20	English
RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MATTERS RELATING TO RULE 13.92 OF THE LISTING RULES Board/Management Information	2024-12-20	English
VOLUNTARY ANNOUNCEMENT - CDE APPROVAL TO INITIATE A REGISTRATIONAL CLINICAL STUDY OF IRPAGRATINIB (ABSK011) IN PATIENTS WITH HCC Regulatory Filings	2024-12-16	English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL STUDY OF ABSK043, AN ORAL PD-L1 SMALL-MOLECULE INHIBITOR, IN COMBINATION WITH FURMONERTINIB FOR NSCLC Regulatory Filings	2024-12-11	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS PROMISING PRELIMINARY PHASE II STUDY RESULTS OF PIMICOTINIB IN THE TREATMENT OF CGVHD AT THE 66TH ASH ANNUAL MEETING Regulatory Filings	2024-12-08	English
VOLUNTARY ANNOUNCEMENT - ESMO ASIA 2024: ORAL PRESENTATION BY ABBISKO THERAPEUTICS ON UPDATED RESULTS FROM A PHASE I STUDY OF ABSK043, AN ORAL PD-L1 INHIBITOR Regulatory Filings	2024-12-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024 Share Issue/Capital Change	2024-12-05	English
VOLUNTARY ANNOUNCEMENT - U.S. FDA IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR Regulatory Filings	2024-12-03	English
VOLUNTARY ANNOUNCEMENT - FIRST-PATIENT DOSED IN GASTRIC CANCER IN PHASE II CLINICAL STUDY EVALUATING ABSK043, AN ORAL PD-L1 INHIBITOR, IN COMBINATION WITH ABSK061, AN ORAL FGFR2/3 INHIBITOR, FOR Regulatory Filings	2024-11-22	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED RESULTS ON MODEL-INFORMED DOSE SELECTION FOR PIMICOTINIB AT ACOP 2024 Regulatory Filings	2024-11-13	English
INSIDE INFORMATION - POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 MANEUVER STUDY OF PIMICOTINIB IN TGCT PATIENTS AND UPDATED RESULTS FROM PHASE 1 STUDY OF PIMICOTINIB IN TGCT PATIENTS Regulatory Filings	2024-11-12	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT PRELIMINARY PHASE 2 STUDY RESULTS OF PIMICOTINIB FOR THE TREATMENT OF CGVHD AT THE 66TH ASH ANNUAL CONFERENCE Regulatory Filings	2024-11-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024 Regulatory Filings	2024-11-05	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL RESEARCH RESULTS OF ITS PRMT5*MTA AND ORAL KRASG12D PROGRAMS AT THE EORTC-NCI-AACR CONFERENCE Regulatory Filings	2024-10-23	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024 Regulatory Filings	2024-10-07	English
Next Day Disclosure Return - Changes in Issued Share Capital Transaction in Own Shares	2024-09-30	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE AND REPURCHASED SHARES CANCELLATION Transaction in Own Shares	2024-09-30	English
VOLUNTARY ANNOUNCEMENT - ABK3376 OBTAINED IND APPROVAL FROM NMPA Regulatory Filings	2024-09-24	English
2024 INTERIM REPORT Interim / Quarterly Report	2024-09-19	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS UPDATED CLINICAL PROGRESS ON IRPAGRATINIB AND PIMICOTINIB AT ESMO CONGRESS Regulatory Filings	2024-09-15	English
Next Day Disclosure Returns Transaction in Own Shares	2024-09-04	English
Next Day Disclosure Returns Transaction in Own Shares	2024-09-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024 Capital/Financing Update	2024-09-02	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-30	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-29	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-28	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-27	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-26	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-22	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-21	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-20	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-16	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-15	English
Next Day Disclosure Returns Transaction in Own Shares	2024-08-14	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 Interim / Quarterly Report	2024-08-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024 Share Issue/Capital Change	2024-08-06	English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024 Regulatory Filings	2024-08-06	English
DATE OF BOARD MEETING Report Publication Announcement	2024-07-26	English
POSITIVE PROFIT ALERT Earnings Release	2024-07-10	English
Next Day Disclosure Returns Transaction in Own Shares	2024-07-04	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE Transaction in Own Shares	2024-07-04	English
Next Day Disclosure Return - Changes in Issued Share Capital Transaction in Own Shares	2024-07-03	English
Next Day Disclosure Returns Transaction in Own Shares	2024-07-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024 Regulatory Filings	2024-07-02	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-28	English
VOLUNTARY ANNOUNCEMENT - 2024 ESMO-GI \| ABBISKO THERAPEUTICS PRESENTS NEW PHASE II CLINICAL DATA OF IRPAGRATINIB IN COMBINATION WITH ATEZOLIZUMAB FOR ADVANCED HEPATOCELLULAR CARCINOMA Regulatory Filings	2024-06-28	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-25	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-24	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-21	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-20	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-19	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-18	English
TENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION Governance Information	2024-06-18	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 18, 2024 AND AMENDMENTS TO THE ARTICLES Declaration of Voting Results & Voting Rights Announcements	2024-06-18	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-17	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-14	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-13	English
(Revised) Next Day Disclosure Returns Transaction in Own Shares	2024-06-13	English
Next Day Disclosure Returns Transaction in Own Shares	2024-06-12	English
Next Day Disclosure Returns [Correct Document re-issued] Transaction in Own Shares	2024-06-12	English
Next Day Disclosure Return Regulatory Filings	2024-06-11	English
Next Day Disclosure Return Transaction in Own Shares	2024-06-07	English
Next Day Disclosure Return Transaction in Own Shares	2024-06-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024 Major Shareholding Notification	2024-06-04	English
Next Day Disclosure Return Transaction in Own Shares	2024-05-31	English
Next Day Disclosure Return Transaction in Own Shares	2024-05-30	English
Next Day Disclosure Return Transaction in Own Shares	2024-05-29	English
Next Day Disclosure Return Transaction in Own Shares	2024-05-28	English
Next Day Disclosure Return Transaction in Own Shares	2024-05-24	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES THE INITIATION OF A CLINICAL STUDY EVALUATING ABSK043 IN COMBINATION WITH FURMONERTINIB MESYLATE TABLETS FOR THE TREATMENT OF ADVANCED NON-SMALL Regulatory Filings	2024-05-09	English
Next Day Disclosure Return Transaction in Own Shares	2024-05-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024 Regulatory Filings	2024-05-02	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-30	English
APPOINTMENT OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES Board/Management Information	2024-04-29	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-26	English
VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED ODD BY FDA Regulatory Filings	2024-04-25	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-24	English
RESIGNATION OF JOINT COMPANY SECRETARY Board/Management Information	2024-04-24	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-23	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-22	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-19	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-18	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-17	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-17	English
Notification Letter and Reply Form to Registered Shareholders Report Publication Announcement	2024-04-16	English
Notification Letter and Reply Form to Non-registered Shareholders Report Publication Announcement	2024-04-16	English
FORM OF PROXY FOR THE 2023 ANNUAL GENERAL MEETING AGM Information	2024-04-16	English
NOTICE OF THE ANNUAL GENERAL MEETING AGM Information	2024-04-16	English
PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES RE-ELECTION OF DIRECTORS RE-APPOINTMENT OF AUDITOR PROPOSED AMENDMENTS TO THE NINTH AMENDED AND RESTATED MEMORANDUM AGM Information	2024-04-16	English
2023 Environmental, Social and Governance Report Environmental & Social Information	2024-04-16	English
2023 Annual Report Annual Report	2024-04-16	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-15	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-12	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-11	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-10	English
VOLUNTARY ANNOUNCEMENT - 3 Pre-clinical Research Results Presented at AACR 2024 Regulatory Filings	2024-04-10	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-09	English
VOLUNTARY ANNOUNCEMENT - Pimicotinib (ABSK021) Patient Enrollment Completed Regulatory Filings	2024-04-09	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-08	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-08	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-03	English
Next Day Disclosure Return Transaction in Own Shares	2024-04-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024 Regulatory Filings	2024-04-02	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-28	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-27	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-26	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-25	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-22	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-21	English
Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2024-03-20	English
Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2024-03-20	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-20	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-19	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-18	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-15	English
Next Day Disclosure Return Transaction in Own Shares	2024-03-13	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE Transaction in Own Shares	2024-03-13	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOC Annual Report	2024-03-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024 Regulatory Filings	2024-03-04	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DELIVERED ORAL PRESENTATION OF PRELIMINARY FIRST-IN-HUMAN TRIAL RESULTS OF ITS HIGHLY SELECTIVE FGFR2/3 INHIBITOR ABSK061 AT THE 2024 ESMO TAT Regulatory Filings	2024-02-28	English
DATE OF BOARD MEETING Regulatory Filings	2024-02-26	English
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT DOSE OF NEXT-GENERATION EGFR EXON20INS INHIBITOR ABSK112 COMPLETED BY ABBISKO THERAPEUTICS Regulatory Filings	2024-02-23	English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTO A LICENSING AGREEMENT FOR PIMICOTINIB (ABSK021) WITH MERCK Capital/Financing Update	2024-02-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024 Share Issue/Capital Change	2024-02-05	English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE POST-IPO RSU SCHEME Transaction in Own Shares	2024-02-01	English
VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB GRANTED ODD BY EMA Regulatory Filings	2024-01-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023 Major Shareholding Notification	2024-01-05	English
VOLUNTARY ANNOUNCEMENT - CD73 INHIBITOR ABSK051 COMPLETED THE FIRST PATIENT DOSE Regulatory Filings	2024-01-03	English